Tvardi Therapeutics, Inc. lost $3.26 per diluted share in fiscal year 2025. Over the trailing 12 months, Q3 FY2025 through Q2 FY2026, the same line adds up to a loss of $2.77 per diluted share. The table below carries 14 fiscal years, from 2012 to 2025, and the quarters Tvardi Therapeutics, Inc. has filed alongside them.
FY2025 annual
EPS (Diluted)-$3.26
Ticker history: CARA became
TVRD
(Tvardi Therapeutics, Inc.) on .
Earlier news and filings retain their original names and dates.
View CARA history.
Source SEC Filings (10-K/10-Q)Latest period Q2 FY2026, ended Jun 30, 2026ReportedCurrency USD
Annual figures, oldest first. Point at a bar to read its period.
TVRD EPS (Diluted) by Fiscal Year
Figures are as reported in USD. Each change compares the year with the year before it, and each column links to the filing it was taken from.
Diluted earnings per share divides net income by the share count the company would have if every option and convertible security were exercised, which is the more conservative of the two per-share figures a filer reports.
Tvardi Therapeutics, Inc. lost $3.26 per diluted share in fiscal year 2025.
Tvardi Therapeutics, Inc. (TVRD) reported a loss of $2.77 per diluted share over the trailing 12 months, Q3 FY2025 through Q2 FY2026, summed from the four most recent quarterly filings.
Tvardi Therapeutics, Inc. (TVRD) reported -$0.69 in diluted earnings per share in Q2 2026. The change from the same quarter a year earlier is not meaningful, because that figure was zero or negative.
Diluted earnings per share divides net income by the share count the company would have if every option and convertible security were exercised, which is the more conservative of the two per-share figures a filer reports. This page lists what Tvardi Therapeutics, Inc. (TVRD) reported on that line in every period on record.
